This trial showed the very favorable tolerability, safety, and pharmacokinetic profile of REL-1017.
Reliance, Relmada’s Phase 3 clinical development program for REL-1017, is designed to support FDA approval for the adjunctive treatment of MDD. Recent data from Reliance completed studies confirm potential efficacy in MDD and a very favorable safety profile with the lack of meaningful risk of abuse. New Phase 3 clinical trials in the Reliance program will endeavor to provide the necessary evidence to support a successful FDA submission for REL-1017, a new NMDA inhibitor as an effective and safe adjunctive treatment for MDD. You can learn more at reliancestudies.com and relightstudies.com.
Scroll to see more
We have obtained a novel NeuroplastogenTM program from Arbormetis LLC and have synthesized a series of novel esmethadone and psilocybin derivatives. NeuroplastogenTM drugs have the potential to restore impaired neural plasticity without dissociative effects (Cooper 2023). Leveraging our understanding of neural plasticity, we are in the process of selecting the most promising candidates targeting neurological and psychiatric disorders for clinical development.
We are developing a novel modified release psilocybin formulation that has shown promising activity in pre-clinical studies for the treatment of obesity and other metabolic diseases. A Phase 1 single ascending dose (SAD) clinical study will commence in 2024.